CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 144 enrolled
Drug / intervention
Continuous Positive Airway Pressure (CPAP)device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00393913
NCT00393913N/ACompleted
CompareCT.gov

Relating Sleep Disordered Breathing to Daytime Function

NYU Langone Health·observational·Posted Oct 31, 2006·Updated Aug 5, 2016

In Brief

An observational study evaluating Continuous Positive Airway Pressure (CPAP) for Sleep Apnea, Obstructive. Completed, enrolled 144 participants across 1 site.

Detailed Summary

Obstructive sleep apnea (OSA) is a serious sleep disorder in which a person repeatedly stops breathing, or experiences shallow breathing for short periods of time during sleep. Daytime sleepiness is a common symptom of OSA and may affect an individual's level of alertness throughout the day. The primary purpose of this study is to evaluate the relationship between the severity of sleep-disordered breathing and levels of daytime alertness at baseline (untreated state) in a group of subjects with and without sleep apnea. In addition the change in daytime sleepiness in subjects with sleep apnea being treated with a continuous positive airway pressure (CPAP) machine, a common treatment for OSA will also be assessed.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsSleep Apnea, Obstructive
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI)

Timeline

N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 31, 2006
Enrollment StartOct 1, 2006
Primary CompletionMay 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 19.7 years ago

Interventions

Continuous Positive Airway Pressure (CPAP)device

Positive airway pressure delivered via a nasal mask titrated to a therapeutic level to eliminate all sleep disordered breathing to be used every night for 4-6 weeks.